News Sentiment

CGEM sentiment intelligence

Cullinan Oncology LLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.13 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

86/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+2.8% over one week, +32.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Cullinan CSO sells shares, exercises options | CGEM Insider Trading

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 86/100 classification
One-week reaction 2.8% Price confirming higher
Trend fit Trend active 32.3% over four weeks
Fair value 44.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 33
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 6
Stock Traders Daily 4
GlobeNewswire 4
Investing.com 3
Seeking Alpha 3
simplywall.st 3
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 10
Guidance 2
Analyst action 1
Balance sheet 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Stock Titan Direct company coverage

Cullinan CSO sells shares, exercises options | CGEM Insider Trading

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, executed an exercise-and-sell transaction. She sold 8,000 shares of common stock at a weighted average price of $17.82 per share under a pre-arranged Rule 10b5-1 trading plan and simultaneously exercised stock

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

CGEM (NASDAQ) insider resale notice: 8,000 shares proposed, prior 10b5-1 sales noted

A Form 144 filing by CGEM (Cullinan Therapeutics, Inc.) indicates a proposed resale of 8,000 shares of common stock from insider-related sources. This includes 4,000 shares from exercised stock options (dated 07/06/2026) and 4,000 shares from Restricted Stock Units (dated 02/22/2

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:11
Source
Stock Titan
Stock Traders Daily Direct company coverage

Why (CGEM) Price Action Is Critical for Tactical Trading

This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM) for tactical trading, identifying a weak near-term sentiment but strong mid- and long-term outlook. It highlights a significant 53.2:1 risk-reward short setup and provides specific AI-generated trading strategies includi

Tone
Neutral 50/100
Event
Guidance
Published
06 Jul 2026 11:39
Source
Stock Traders Daily
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) CFO adds 1,541 shares through ESPP purchase

Cullinan Therapeutics' CFO, Mary Kay Fenton, acquired 1,541 shares of company common stock through the 2021 Employee Stock Purchase Plan. The shares were purchased at $8.60 each, based on 85% of the closing price on January 2, 2026, for the period of January 1 to June 30, 2026. F

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) CLO adds 2,470 ESPP shares at $8.60

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, acquired 2,470 shares of common stock at $8.60 per share through the company's 2021 Employee Stock Purchase Plan. This routine transaction, which occurred between January 1 and June 30, 2026, increases her direct hol

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Barchart.com Direct company coverage

EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine

The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as

Tone
Positive 65/100
Event
Earnings
Published
30 Jun 2026 11:11
Source
Barchart.com
Investing.com Nigeria Direct company coverage

Cullinan Oncology stock hits 52-week high at $17.97 By Investing.com

Cullinan Oncology (CGEM) stock recently hit a 52-week high of $17.97, reflecting a significant 127.68% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, the company, with a $1.1 billion market capitalization, continues to show stron

Tone
Positive 74/100
Event
Market update
Published
27 Jun 2026 11:39
Source
Investing.com Nigeria
Sahm Direct company coverage

Cullinan Therapeutics (CGEM) Is Up 31.0% After Autoimmune T Cell Engager Data – Has The Bull Case Changed?

Cullinan Therapeutics (CGEM) stock surged 31.0% after reporting positive Phase 1 data for its T cell engagers, CLN-978 and velinotamig, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. This data indicates strong clinical responses and favorable s

Tone
Positive 65/100
Event
Market update
Published
26 Jun 2026 09:09
Source
Sahm
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (CGEM)

This article provides an in-depth analysis of Cullinan Oncology Inc. (CGEM) using AI models to identify momentum shifts and suggest trading strategies. It highlights strong sentiment across all time horizons supporting an overweight bias and points out that resistance is being te

Tone
Positive 64/100
Event
Market update
Published
25 Jun 2026 10:22
Source
Stock Traders Daily
Investing.com Direct company coverage

Cullinan Oncology stock hits 52-week high at $17.97

Cullinan Oncology LLC's stock reached a 52-week high of $17.97, and is currently trading just 1% below this peak. The company has recently reported positive clinical trial data, received Orphan Drug Designation for CLN-049, and held its Annual Meeting of Stockholders. Analysts fr

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 07:11
Source
Investing.com
Quartr Direct company coverage

Cullinan Therapeutics (CGEM) Citi’s 2026 Virtual Oncology Leadership Summit Summary

Cullinan Therapeutics discussed its pipeline strategy at Citi’s 2026 Virtual Oncology Leadership Summit, highlighting T-cell engagers CLN-978 for autoimmune diseases and CLN-049 for AML as key catalysts for the year. The company aims for transformative potential with first-in-cla

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 06:39
Source
Quartr
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant

Cullinan Therapeutics director Andrew R. Allen was granted stock options for 21,781 shares of common stock with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the company's next annual meeting, provided his continued board service. Thi

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 05:10
Source
Stock Titan
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike

Cullinan Therapeutics director Mary Thistle was granted 25,319 stock options with an exercise price of $13.55 per share. The options will vest in full by June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This grant is part of h

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) grants director 25,319 stock options

Cullinan Therapeutics (CGEM) director Anthony Rosenberg was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or at the company's next annual meeting, provided he continues his board service. The Form 4 fili

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Cullinan Therapeutics (CGEM) grants director Mittie Doyle 21,781 stock options

Cullinan Therapeutics director Mittie Doyle was granted 21,781 stock options at an exercise price of $13.55 per share. The options will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service as a director. This trans

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Cullinan Therapeutics shareholders elect directors and approve proposals at annual meeting

Cullinan Therapeutics (NASDAQ: CGEM) shareholders elected two Class III directors for three-year terms, ratified KPMG LLP as the independent registered public accounting firm, and approved an advisory vote on executive compensation at their annual meeting. The biotech company has

Tone
Positive 65/100
Event
Market update
Published
17 Jun 2026 16:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM)

Cullinan Therapeutics director David D. Meek was granted 25,319 stock options with an exercise price of $13.55 per share. These options will vest in full by June 16, 2027, or the date of the company's next annual meeting, contingent on his continued service as a director. This gr

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 10:11
Source
Stock Titan
Stock Titan Direct company coverage

Cullinan Therapeutics (NASDAQ: CGEM) shareholders back directors, KPMG and pay

Cullinan Therapeutics (NASDAQ: CGEM) shareholders held their Annual Meeting on June 16, 2026, where they elected two Class III directors, Nadim Ahmed and Stephen Webster, to three-year terms. They also ratified KPMG LLP as the independent registered accounting firm for 2026 and a

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 21:09
Source
Stock Titan
Stock Traders Daily Direct company coverage

Avoiding Lag: Real-Time Signals in (CGEM) Movement

Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near and mid-term sentiment but a strong long-term outlook, according to AI models. The article details three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss l

Tone
Neutral 50/100
Event
Guidance
Published
14 Jun 2026 09:10
Source
Stock Traders Daily
Stock Titan Direct company coverage

[8-K] Cullinan Therapeutics, Inc. Reports Material Event

Cullinan Therapeutics (NASDAQ: CGEM) has reported early-stage clinical data for its T cell engager programs CLN-978 and velinotamig, targeting autoimmune diseases. CLN-978 showed robust efficacy, including remission in a rheumatoid arthritis patient, and velinotamig demonstrated

Tone
Positive 65/100
Event
Market update
Published
11 Jun 2026 01:40
Source
Stock Titan
grafa.com Direct company coverage

Cullinan Therapeutics reports promising autoimmune trial data

Cullinan Therapeutics announced promising initial clinical data for its dual-targeting T-cell engager, CLN-978, showing its potential in autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company reported clinical remissions and B-cell

Tone
Positive 70/100
Event
Market update
Published
10 Jun 2026 15:38
Source
grafa.com
Investing.com Direct company coverage

Cullinan reports clinical data for autoimmune drug candidates

Cullinan Therapeutics Inc. reported promising clinical data for two T cell engager drug candidates, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. Despite a recent stock decline, the company saw positive patient

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 12:38
Source
Investing.com
Stock Titan Direct company coverage

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Cullinan Therapeutics announced new clinical data from its T cell engager programs targeting CD19 (CLN-978) and BCMA (velinotamig) for autoimmune diseases. CLN-978 showed potential for immune reset and clinical remissions in systemic lupus erythematosus (SLE) and rheumatoid arthr

Tone
Positive 72/100
Event
Market update
Published
10 Jun 2026 11:10
Source
Stock Titan